Exploring the Anti-Cervical Cancer Effect and Hepatotoxicity Risk of Gossypol Based on Untargeted Metabolomics and

Jinyan Li1,2, Parwen Parhat1, Yinglan Ma1

  • 1State Key Laboratory of Pathogenesis, Prevention and Treatment of High Incidence Diseases in Central Asia, College of Pharmacy, Xinjiang Medical University, Urumqi 830011, China.

Insights

Gossypol effectively inhibits cervical cancer growth in mice but poses a hepatotoxicity risk. Further research is needed to understand the molecular mechanisms of gossypol-induced liver injury and its therapeutic potential.

Area of Science:

  • Oncology
  • Toxicology
  • Pharmacology

Background:

  • Cervical cancer remains a significant global health challenge.
  • Gossypol, a natural compound, has shown potential anticancer properties.
  • Understanding gossypol's efficacy and safety profile is crucial for therapeutic development.

Purpose of the Study:

  • To evaluate gossypol's anti-cervical cancer effects in a mouse model.
  • To investigate the risk and mechanisms of gossypol-induced liver damage.
  • To identify molecular targets and pathways involved in gossypol's action and toxicity.

Main Methods:

  • Subcutaneous cervical cancer xenograft model in nude mice.
  • Assessment of tumor volume, organ morphology, and serum cytokines (IL-6, IL-10, TNF-α).
  • Protein expression analysis (Western blotting), untargeted metabolomics, network toxicology, KEGG/GO enrichment, and molecular docking.

Main Results:

  • Gossypol significantly suppressed cervical cancer tumor growth.
  • Gossypol reduced expression of PIK3R2, GRB2, and MAPK1.
  • Identified 1464 differential metabolites and key hepatotoxicity targets (MTOR, TNF, CASP3, BCL2L1, BCL2) and pathways (malignancy, HIF-1 signaling, apoptosis).

Conclusions:

  • Gossypol exhibits significant therapeutic potential against cervical cancer.
  • Gossypol-induced hepatotoxicity involves multiple targets and pathways.
  • Further investigation is warranted to elucidate gossypol's mechanisms and optimize its clinical application.

Related Concept Videos

Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
76
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
256
Mutagenicity and Carcinogenicity01:25

Mutagenicity and Carcinogenicity

Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...
2.1K
Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug01:14

Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug

In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...
296
Drug Toxicity: Risk factors01:24

Drug Toxicity: Risk factors

Adverse Drug Reactions (ADRs) are potential complications that arise during pharmacotherapy, influenced by multiple risk factors. Age plays a significant role; both neonates and the elderly are at heightened risk due to their respective immature and diminished metabolic and elimination processes. Gender also impacts ADRs, with females experiencing a 1.5 to 1.7-fold greater risk than males, which may be linked to pharmacokinetic, pharmacodynamic, and hormonal differences. Notably, neonates, the...
168
Pharmacogenetics of Drug Metabolism: Overview01:27

Pharmacogenetics of Drug Metabolism: Overview

Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
111